Latest Us Expansion News

Cobram Estate Olives reported a widened half-year loss driven by higher oil costs and operating expenses, while progressing its US growth strategy with a major California acquisition.

Telix Pharmaceuticals delivered a strong 56% revenue increase in 2025, driven by U.S. sales of Illuccix and the launch of Gozellix, while advancing its therapeutic pipeline and expanding global manufacturing capabilities. Despite a net loss, the company is investing heavily in R&D and sustainability initiatives aligned with climate-related disclosures.

Guzman y Gomez has reported a robust first half of FY26, delivering strong revenue and profit growth alongside significant restaurant network expansion in Australia and the US.

Cyclopharm Limited is rapidly scaling its US presence for Technegas®, securing new contracts across federal institutions and major health networks in four key regions. The company aims for up to 300 installations by late 2026, boosting recurring revenue streams.

Cyclopharm has achieved a key milestone with Technegas approved for clinical use at the US National Institutes of Health, marking a strategic advance in its American expansion. Installation is imminent, leveraging a federal procurement framework that could broaden Technegas applications beyond pulmonary embolism.

Adherium Limited launches a A$7.52 million equity raising to fund commercial expansion of its Hailie SmartInhaler remote patient monitoring platform targeting asthma and COPD patients in the US. The company aims to scale patient numbers and progress towards value-based care contracts with major insurers.

American Tungsten & Antimony Ltd (ASX, AT4) has produced its first antimony ingots from its Utah project, validating its processing approach and advancing its US growth ambitions including a planned Nasdaq listing.

Cyclopharm Limited is accelerating its US market push for Technegas with a A$16 million capital raise following a record 2025 sales performance. The company aims to expand its US installations and advance new clinical applications beyond pulmonary embolism.

Resolution Minerals has taken a significant step towards expanding its footprint in the US capital markets by lodging a registration statement with the SEC and launching an ADR facility, while divesting a non-core Alaskan asset to focus on key US projects.

Xero Limited has outlined a bold AI strategy and detailed the integration of Melio to accelerate its US market growth, supported by new financial disclosures and a clear path to profitability.

Xero Limited reveals new AI product demonstrations and updates on Melio’s integration, reaffirming ambitious US growth and FY28 revenue targets.

Orthocell Ltd reports steady progress in commercialising its nerve repair product Remplir in the US, with sales growth, expanded distributor networks, and manufacturing upgrades underpinning its path to profitability.